Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Non-Current Liabilities (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Other Non-Current Liabilities data on record, last reported at $18.5 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 2668.06% year-over-year to $18.5 million; the TTM value through Dec 2025 reached $18.5 million, up 2668.06%, while the annual FY2025 figure was $18.5 million, 2668.06% up from the prior year.
  • Other Non-Current Liabilities reached $18.5 million in Q4 2025 per RVMD's latest filing, up from $2.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $18.5 million in Q4 2025 and bottomed at $219000.0 in Q2 2022.
  • Average Other Non-Current Liabilities over 5 years is $2.7 million, with a median of $1.4 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 89.71% in 2024, then surged 2668.06% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $634000.0 in 2021, then plummeted by 52.52% to $301000.0 in 2022, then soared by 2063.46% to $6.5 million in 2023, then plummeted by 89.71% to $670000.0 in 2024, then soared by 2668.06% to $18.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $18.5 million in Q4 2025, $2.5 million in Q3 2025, and $7.2 million in Q2 2025.